Timor-LesteTuberculosis profile
Population  2016 1.3 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.3 (0.75–1.9) 100 (59–150)
Mortality (HIV+TB only) <0.01 (0–0.035) 0.29 (0–2.7)
Incidence  (includes HIV+TB) 6.3 (4.1–9) 498 (322–712)
Incidence (HIV+TB only) 0.059 (0.038–0.084) 4.6 (3–6.6)
Incidence (MDR/RR-TB)** 0.21 (0.13–0.28) 16 (10–22)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.37 (0.22–0.51) 2.2 (1.3–3) 2.6 (1.6–3.6)
Males 0.42 (0.25–0.58) 3.3 (2–4.7) 3.8 (2.3–5.2)
Total 0.79 (0.48–1.1) 5.5 (3.4–7.7) 6.3 (4.1–9)
TB case notifications, 2016  
Total cases notified 3 620
Total new and relapse 3 607
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status 45%
          - % pulmonary 85%
          - % bacteriologically confirmed among pulmonary 61%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 57% (40–88)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.21 (0.1–0.34)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 23 1%
          - on antiretroviral therapy 23 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  100
(88–110)
Estimated % of TB cases with MDR/RR-TB 2.8% (2.4–3.1) 13% (10–15)  
% notified tested for rifampicin resistance 37% 96% 1 421
MDR/RR-TB cases tested for resistance to second-line drugs   6
Laboratory-confirmed cases MDR/RR-TB: 6, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 6, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 87% 1 650
Previously treated cases, excluding relapse, registered in 2015 75% 12
HIV-positive TB cases registered in 2015 68% 19
MDR/RR-TB cases started on second-line treatment in 2014 100% 3
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (93–100)
TB financing, 2017  
National TB budget (US$ millions) 1.9
Funding source: 11% domestic, 89% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-19 Data: www.who.int/tb/data